EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma

Stefan Habringer, Uta M Demel, Anne-Katrin Fietz, Felicitas Lammer, Roland Schroers, Silvia Hofer, Osnat Bairey, Jan Braess, Anna Sofia Meier-Stiegen, Reingard Stuhlmann, Martin Schmidt-Hieber, Johannes Hoffmann und 26 weitere

European Journal of Cancer · 2024-01 · 196 · 113436

DOI: 10.1016/j.ejca.2023.113436 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Cancer, 2024-01. Verfasst von Stefan Habringer und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie U…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Hematopoietic Stem Cell Transplantation, Central Nervous System Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Riemser Pharma GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Secondary central nervous system lymphoma (SCNSL) confers a dismal prognosis and treatment advances are constrained by the lack of prospective studies and real-world treatment evidence. METHODS: Patients with SCNSL of all entities were included at first diagnosis and patient characteristics, treatment data, and outcomes were prospectively collected in the Secondary CNS Lymphoma Registry (SCNSL-R) (NCT05114330). FINDINGS: 279 patients from 47 institutions were enrolled from 2011 to 2022 and 243 patients (median age: 66 years; range: 23-86) were available for analysis. Of those, 49 (20 %) patients presented with synchronous (cohort I) and 194 (80 %) with metachronous SCNSL (cohort II). The predominant histology was diffuse large B-cell lymphoma (DLBCL, 68 %). Median overall survival (OS) from diagnosis of CNS involvement was 17·2 months (95 % CI 12-27·5), with longer OS in cohort I (60·6 months, 95 % CI 45·5-not estimable (NE)) than cohort II (11·4 months, 95 % CI 7·8-17·7, log-rank test p < 0.0001). Predominant induction regimens included R-CHOP/high-dose MTX (cohort I) and high-dose MTX/cytarabine (cohort II). Rituximab was used in 166 (68 %) of B-cell lymphoma. Undergoing consolidating high-dose therapy and autologous hematopoietic stem cell transplantation (HDT-ASCT) in partial response (PR) or better was associated with longer OS (HR adjusted 0·47 (95 % CI 0·25-0·89), p = 0·0197). INTERPRETATION: This study is the largest prospective cohort of SCNSL patients providing a comprehensive overview of an international real-world treatment landscape and outcomes. Prognosis was better in patients with SCNSL involvement at initial diagnosis (cohort I) and consolidating HDT-ASCT was associated with favorable outcome in patients with PR or better.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseHematopoietic Stem Cell TransplantationCentral Nervous System NeoplasmsHumansAgedProspective StudiesAntineoplastic Combined Chemotherapy ProtocolsRituximabTreatment OutcomeTransplantation, AutologousRetrospective StudiesObservational Studies as Topic

Stichwörter der Autor:innen

Autologous stem cell transplantationHigh-dose chemotherapyReal-world dataRegistry studySCNSLSecondary Central Nervous System Lymphoma

Substanzen

Rituximab

Autor:innen und Institutionen

  • Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany;…
  • Institute of Biostatistics and Clinical Epidemiology, Charité - Universitätsmedizin, Berlin, Germany.
  • Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Department of Medicine, Hematology and Oncology, Ruhr University Bochum, Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH, Bochum, Germany.
  • Division Medical Oncology Cantonal Hospital Luzern, Luzern, Switzerland; Department of Neurology, University Hospital Zürich, Zürich, Switzerland.
  • Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Tel Aviv University, Tel Aviv, Israel.

Förderung

  • Riemser Pharma GmbH

Zitieren

APA

Habringer, S., Demel, U. M., Fietz, A. K., Lammer, F., Schroers, R., Hofer, S., Bairey, O., Braess, J., Meier-Stiegen, A. S., Stuhlmann, R., Schmidt-Hieber, M., Hoffmann, J., Zinngrebe, B., Kaiser, U., Reimer, P., Möhle, R., Fix, P., Höffkes, H. G., Langenkamp, U., …, & Keller, U. (2024). A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma. European Journal of Cancer, 196, 113436. https://doi.org/10.1016/j.ejca.2023.113436

Vancouver

Habringer S, Demel UM, Fietz AK, Lammer F, Schroers R, Hofer S, et al. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma. European Journal of Cancer. 2024;196:113436. doi:10.1016/j.ejca.2023.113436

BibTeX
@article{Habringer2024,
  author = {Habringer, Stefan and Demel, Uta M and Fietz, Anne-Katrin and Lammer, Felicitas and Schroers, Roland and Hofer, Silvia and Bairey, Osnat and Braess, Jan and Meier-Stiegen, Anna Sofia and Stuhlmann, Reingard and Schmidt-Hieber, Martin and Hoffmann, Johannes and Zinngrebe, Bettina and Kaiser, Ulrich and Reimer, Peter and Möhle, Robert and Fix, Peter and Höffkes, Heinz-Gert and Langenkamp, Ulrich and Büschenfelde, Christian Meyer Zum and Hopfer, Olaf and Stoltefuß, Andrea and La Rosée, Paul and Blasberg, Henning and Jordan, Karin and Kaun, Stephan and Meurer, Anna and Unteroberdörster, Meike and von Brünneck, Ann-Christin and Capper, David and Heppner, Frank L and Chapuy, Björn and Janz, Martin and Schwartz, Stefan and Konietschke, Frank and Vajkoczy, Peter and Korfel, Agnieszka and Keller, Ulrich},
  title = {A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma},
  journal = {European Journal of Cancer},
  year = {2024},
  volume = {196},
  pages = {113436},
  doi = {10.1016/j.ejca.2023.113436}
}
Kostenlos starten →